Equities research analysts at Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a report released on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $32.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 94.17% from the stock’s current price.
Separately, Guggenheim assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price objective on the stock.
View Our Latest Stock Analysis on Sionna Therapeutics
Sionna Therapeutics Price Performance
About Sionna Therapeutics
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
- Five stocks we like better than Sionna Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- What does consumer price index measure?
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What Are Treasury Bonds?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
